[Therapeutic effects of micronomicin on experimental infections in mice by intravenous administration].
Protective effects of intravenous administration of micronomicin (MCR) on mouse experimental infections were investigated. Mice were better protected by intravenous administration in S. marcescens T-55 experimental infection than subcutaneous administration. No remarkable differences were found between the two administrations in cases of P. aeruginosa BMH No. 1 and E. coli GN 2411-5 infections. Intravenous administrations of MCR, gentamicin (GM), dibekacin (DKB), amikacin (AMK) and sisomicin (SISO) protected the infection of P. aeruginosa BMH No. 1 in a similar extent. MCR was more effective intravenously than AMK; DKB and AMK; DKB, AMK and SISO in experimental infections of E. coli GN 2411-5; S. marcescens T-55; P. aeruginosa KY-8510 harboring aminoglycoside inactivating enzyme AAC(6')-4, respectively.
D000617:Aminoglycosides / Q000008:administration & dosage; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004353:Drug Evaluation, Preclinical; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005839:Gentamicins; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D011552:Pseudomonas Infections / Q000188:drug therapy*; D012706:Serratia marcescens
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; C037545:micronomicin